Novartis (NVS) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Here's Why Novartis (NVS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 glomerulopathy.
Novartis Reports Updated Positive Data From Phase III SMA Program
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
Novartis scraps use of diverse panels for hires in US
Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told Reuters on Wednesday, citing the changing legal and policy landscape surrounding diversity in the U.S.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Novartis CEO says it is watching US reciprocal tariff policy 'very carefully'
Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy proposed by the United States would unfold in early April, Chief Executive Vas Narasimhan said in Tokyo. U.S. President Donald Trump last month flagged potential import duties of about 25% on pharmaceuticals as part of measures affecting other industries, including semiconductors and automobiles, as he seeks to reshape global trade.
NFL signs Novartis as first pharmaceutical partner-source
The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis , a league source told Reuters on Thursday.
Novartis not panicking over potential US pharmaceutical tariffs, chairman says
Novartis is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the drug maker's Chairman Joerg Reinhardt said in an interview published on Thursday.
Final Trade: NVS, XLU, GM
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta
The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved treatment.
Why Novartis Remains A 'Buy' After Beating Expectations Again
At the end of January, Novartis pleasantly surprised me with its financial results for Q4 2024, which were achieved, in part, due to the strong performance of its oncology franchise. So, sales of Pluvicto, a medication for the treatment of prostate cancer, reached $351 million in the fourth quarter of 2024, an increase of 28.6% year-on-year. Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector.
